The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Induction of myelodysplasia by myeloid-derived suppressor cells
Open accessAbstract
Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited components to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppressive cytokines IL-10 and TGF-β by immature myeloid cells. S100A9 transgenic mice displayed bone marrow accumulation of MDSC accompanied by development of progressive multilineage cytopenias and cytological dysplasia. Importantly, early forced maturation of MDSC by either all-trans-retinoic acid treatment or active immunoreceptor tyrosine-based activation motif–bearing (ITAM-bearing) adapter protein (DAP12) interruption of CD33 signaling rescued the hematologic phenotype. These findings indicate that primary bone marrow expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the development of MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MDSCs are sufficient to create an MDS phenotype in murine experiments, and targeting them or their expansion leads to reconstitution of normal hematopoiesis.76,77”
From Inflammatory bone marrow microenvironment (2019) · cites this paper as [76]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Self-citationLanier, L. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115526 · Cited by 2,765
Siglecs and their roles in the immune system
Crocker, P. R., Paulson, J. C., & Varki, A. P. (2007) · Nature reviews. Immunology · doi:10.1038/nri2056 · Cited by 2,032
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand‐Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,777
Subsets of Myeloid-Derived Suppressor Cells in Tumor-Bearing Mice
Youn, J., Nagaraj, S., Collazo, M. M., & Gabrilovich, D. I. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5791 · Cited by 1,645
Self-citationVogl, T., Tenbrock, K., Ludwig, S., Leukert, N., Ehrhardt, C., van Zoelen, M. A. D., Nacken, W., Foell, D., van der Poll, T., Sorg, C., et al. (2007) · Nature Medicine · doi:10.1038/nm1638 · Cited by 1,418 · cited 2×
“Given our findings that S100A9 triggers CD33/Siglec 3 signaling and is involved in MDSC activation (17, 18, 37), we generated S100A9Tg mice to study MDSC-associated inflammation (37).”
Ravetch, J. V., & Lanier, L. L. (2000) · Science · doi:10.1126/science.290.5489.84 · Cited by 1,278
Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia
Raaijmakers, M. H. G. P., Mukherjee, S., Guo, S., Zhang, S., Kobayashi, T., Schoonmaker, J. A., Ebert, B. L., Al-Shahrour, F., Hasserjian, R. P., Scadden, E. O., et al. (2010) · Nature · doi:10.1038/nature08851 · Cited by 1,115
Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells
Lanier, L. L., Corliss, B. C., Wu, J., Leong, C. C., & Phillips, J. H. (1998) · Nature · doi:10.1038/35642 · Cited by 907
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M. L., Nacken, W. K. F., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 904
Self-citation
Research works printed but not linked: 3
- Kapanadze, 2013, J Hepatol., pii, S0168-8278(13)00421-2
- Xu, 2010, J Biomed Biotechnol., 2010, 105940
- Ioachim HL Medeiros LJ Cytopathology. In: Iochim’s Lymph Node Pathology. 4th ed. Philadelphia, Pennsylvania, USA: Wolters Kluwer/Lippincott Williams &Wilkins; 2008 21 22
Cited by
Sorted by citations
Items 101–200 of 316
Bone marrow immunity and myelodysplasia
Lambert, C., Wu, Y., & Aanei, C. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00172 · Cited by 42
Myeloid Derived Suppressor Cells in Chronic Myeloid Leukemia
Giallongo, C., Parrinello, N. L., Brundo, M. V., Raccuia, S. A., Rosa, M. D., Cava, P. L., & Tibullo, D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00107 · Cited by 42
KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice
Wei, Y., Zheng, H., Bao, N., Jiang, S., Bueso-Ramos, C., Khoury, J. D., Class, C. A., Lu, Y., Lin, K., Yang, H., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018024166 · Cited by 44
McLemore, A. F., Hou, H., Meyer, B. S., Lam, N. B., Ward, G., Aldrich, A. L., Rodrigues, M. A., Vedder, A., Zhang, L., Padron, E., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.159430 · Cited by 42
Self-citationKomrokji, R. S., Mailloux, A. W., Chen, D.-T., Sekeres, M. A., PAQUETTE, R. L., Fulp, W. J., Sugimori, C., Paleveda, J., Maciejewski, J. P., List, A. F., et al. (2014) · Haematologica · doi:10.3324/haematol.2012.083345 · Cited by 41
Self-citationCremers, N. A. J., van den Bosch, M. H. J., van Dalen, S. C. M., Ceglie, I. D., Ascone, G., van de Loo, F., Koenders, M. I., van der Kraan, P. M., Sloetjes, A. W., Vogl, T., et al. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1426-6 · Cited by 42
Ward, G., McGraw, K. L., Aghababazadeh, F. A., Meyer, B. S., McLemore, A. F., Vincelette, N. D., Lam, N. B., Aldrich, A. L., Ali, N. H. A., Padron, E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003475 · Cited by 42
Self-citationMyeloid-Derived Suppressor Cells and Mesenchymal Stem/Stromal Cells in Myeloid Malignancies
Kapor, S., & Santibanez, J. F. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132788 · Cited by 41
The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
Ren, R., Xiong, C., Ma, R., Wang, Y., Yue, T., Yu, J., & Shao, B. (2023) · MedComm · doi:10.1002/mco2.323 · Cited by 42
Komrokji, R. S., Wei, S., Mailloux, A. W., Zhang, L., Padron, E., Sallman, D. A., Lancet, J. E., Tinsley, S., Nardelli, L. A., Pinilla-Ibarz, J. A., et al. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.12.005 · Cited by 40
Self-citationMyeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin
Yu, S., Ren, X., & Li, L. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00296-9 · Cited by 42
Granzymes in health and diseases: the good, the bad and the ugly
Cigalotto, L., & Martinvalet, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1371743 · Cited by 41
The immune landscape of myelodysplastic syndromes
Fozza, C., Crobu, V., Isoni, M. A., & Dore, F. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.08.016 · Cited by 39
Therapeutic targeting of the inflammasome in myeloid malignancies
Chakraborty, S., Shapiro, L. C., de Oliveira, S., Rivera-Peña, B., Verma, A. K., & Shastri, A. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00547-8 · Cited by 40
Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator.
Chen, Y., Liu, R., Li, C., Song, Y., Liu, G., Huang, Q., Yu, L., Zhu, D., Lu, C. C., Lü, A., et al. (2021) · PubMed · Cited by 46
Disordered Immune Regulation and its Therapeutic Targeting in Myelodysplastic Syndromes
Ivy, K. S., & Ferrell, P. B. (2018) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-018-0463-9 · Cited by 37
TIFAB Regulates USP15-Mediated p53 Signaling during Stressed and Malignant Hematopoiesis
Niederkorn, M., Hueneman, K. M., Choi, K., Varney, M., Romano, L. M., Pujato, M., Greis, K., Inoue, J., Meetei, R. A., & Starczynowski, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.01.093 · Cited by 36
Vegivinti, C. T. R., Keesari, P. R., Veeraballi, S., Maia, C., Mehta, A. K., Lavu, R. R., Thakur, R., Tella, S. H., Patel, R. J., Kakumani, V. K., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00422-1 · Cited by 43
Mesenchymal stromal cells in myeloid malignancies
Schroeder, T. A., Geyh, S., Germing, U., & Haas, R. R. (2016) · Blood Research · doi:10.5045/br.2016.51.4.225 · Cited by 38
Modulation of T-cell function by myeloid-derived suppressor cells in hematological malignancies
Bhardwaj, V., & Ansell, S. M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1129343 · Cited by 34
Wang, W., Zou, R., Qiu, Y., Liu, J., Yu, X., He, T., & Qiu, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.670324 · Cited by 34
SOHO State of the Art & Next Questions: Myelodysplastic Syndromes: A New Decade
Volpe, V. O., Garcia‐Manero, G., & Komrokji, R. S. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.07.031 · Cited by 33
Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes
Itoh, A., & Ridgway, W. M. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s117264 · Cited by 32
Narayan, R., Piérola, A. A., Donnellan, W. B., Molero, A., Abdul‐Hay, M., Platzbecker, U., Subklewe, M. S., Kadia, T. M., Alonso‐Domínguez, J. M., McCloskey, J. K., et al. (2024) · Clinical and Translational Science · doi:10.1111/cts.13742 · Cited by 31
Bronte, G., Calabrò, L., Olivieri, F., Procopio, A. D., & Crinò, L. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00946-6 · Cited by 31
Younos, I., Abe, F., & Talmadge, J. E. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.987141 · Cited by 30
Neutrophil Phenotypes in Coronary Artery Disease
Maréchal, P., Tridetti, J., Nguyen, M.-L., Wéra, O., Jiang, Z., Gustin, M., Donneau, A., Oury, C., & Lancellotti, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051602 · Cited by 30
Přibyl, M., Hodný, Z., & Kubíková, I. (2021) · Genes · doi:10.3390/genes12010108 · Cited by 30
The immunomodulatory role of all-trans retinoic acid in tumor microenvironment
Bi, G., Liang, J., Bian, Y., Shan, G., Besskaya, V., Wang, Q., & Zhan, C. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00860-x · Cited by 32
Cannova, J., Breslin, P., & Zhang, J. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0412-0 · Cited by 29
Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice
Tang, C.-H. A., Chang, S., Hashimoto, A., Chen, Y., Kang, C. W., Mato, A. R., Valle, J. R. D., Gabrilovich, D. I., & Hu, C. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0582 · Cited by 30
Self-citationGbolahan, O. B., Zeidan, A. M., Stahl, M. F., Zaid, M. I. A., Farag, S. S., Paczesny, S., & Koenig, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081660 · Cited by 29
S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy
Razmkhah, F., Kim, S., Lim, S., Dania, A.-J., & Choi, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713382 · Cited by 28
Immunological derangement in Hypocellular Myelodysplastic Syndromes
Serio, B., Risitano, A., Giudice, V., Montuori, N., & Selleri, C. (2014) · Europe PMC (PubMed Central) · doi:10.14273/unisa-230 · Cited by 27
Immunotherapy in Myeloproliferative Diseases
Braun, L. M., & Zeiser, R. (2020) · Cells · doi:10.3390/cells9061559 · Cited by 28
Fan, Z., Peng, M. L., Chen, Y. Y., Xia, Y., Liu, C. Y., Zhao, K., & Zhang, H. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.743354 · Cited by 27
Park, S. J., & Bejar, R. L. (2018) · Current Stem Cell Reports · doi:10.1007/s40778-018-0133-9 · Cited by 28
Bewersdorf, J. P., Shallis, R. M., Sharon, E., Park, S., Ramaswamy, R., Roe, C. E., Irish, J. M., Caldwell, A. B., Wei, W., Yacoub, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05552-4 · Cited by 26
Dufait, I., Pardo, J., Escors, D., Vlaeminck, Y. D., Jiang, H., Keyaerts, M., Ridder, M. D., & Breckpot, K. (2019) · Cancers · doi:10.3390/cancers11060808 · Cited by 26
S100-Alarmins Are Essential Pilots of Postnatal Innate Immune Adaptation
Viemann, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00688 · Cited by 23
Current Limitations and Perspectives of Chimeric Antigen Receptor-T-Cells in Acute Myeloid Leukemia
Maucher, M., Srour, M., Danhof, S., Einsele, H., Hudecek, M., & Yakoub‐Agha, I. (2021) · Cancers · doi:10.3390/cancers13246157 · Cited by 25
Dyserythropoiesis of myelodysplastic syndromes
Lefèvre, C., Bondu, S., Goff, S. L., Kosmider, O., & Fontenay, M. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000325 · Cited by 26
Kipfer, B., Daikeler, T. D., Kuchen, S., Hallal, M., Andina, N. D., Allam, R., & Bonadies, N. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.05.002 · Cited by 24
Myeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes
Han, D., Tao, J., Fu, R., & Shao, Z. (2020) · Innate Immunity · doi:10.1177/1753425920961157 · Cited by 24
Self-citationThe Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes
Kittang, A. O., Sand, K. E., Brenner, A. K., Rye, K. P., & Bruserud, Ø. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071080 · Cited by 24
Vito, A., Salem, O., El-Sayes, N., MacFawn, I., Portillo, A. L., Milne, K., Harrington, D., Ashkar, A. A., Wan, Y., Workenhe, S. T., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02375-9 · Cited by 24
Biology of the bone marrow microenvironment and myelodysplastic syndromes
Rankin, E. B., Narla, A., Park, J. K., Lin, S., & Sakamoto, K. M. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.07.004 · Cited by 24
Choi, D. S., Tremblay, D. A., Iancu‐Rubin, C., & Mascarenhas, J. O. (2017) · Annals of Hematology · doi:10.1007/s00277-016-2915-4 · Cited by 23
Pharmacological modulation of myeloid-derived suppressor cells to dampen inflammation
van Geffen, C., Heiss, C., Deißler, A., & Kolahian, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.933847 · Cited by 23
Novel Strategies for Peptide-Based Vaccines in Hematological Malignancies
Klausen, U., Holmberg, S., Holmström, M. O., Jørgensen, N. G. D., Grauslund, J. H., Svane, I. M., & Andersen, M. H. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02264 · Cited by 22
Mian, S. A., & Bonnet, D. A. (2021) · Cancers · doi:10.3390/cancers13164116 · Cited by 22
Barakos, G. P., & Hatzimichael, E. C. (2022) · Diseases · doi:10.3390/diseases10020033 · Cited by 24
Correlation between myeloid-derived suppressor cells and S100A8/A9 in tumor and autoimmune diseases
Zheng, R., Chen, S., & Chen, S. (2015) · International Immunopharmacology · doi:10.1016/j.intimp.2015.10.014 · Cited by 21
Baishya, J., Everett, J. A., Chazin, W., Rumbaugh, K. P., & Wakeman, C. A. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.898796 · Cited by 24
Clonal hematopoiesis and inflammation: A review of mechanisms and clinical implications
Nathan, D. I., Dougherty, M. L., Bhatta, M., Mascarenhas, J. O., & Marcellino, B. K. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104187 · Cited by 22
Cancer immune therapy for myeloid malignancies: present and future
Holmström, M. O., & Hasselbalch, H. C. (2018) · Seminars in Immunopathology · doi:10.1007/s00281-018-0693-x · Cited by 23
Jørgensen, M. J., Jenum, S., Tonby, K., Mortensen, R. J., Walzl, G., du Plessis, N., & Dyrhol‐Riise, A. M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.4a0720-409rr · Cited by 21
TIRAP drives myelosuppression through an Ifnγ–Hmgb1 axis that disrupts the endothelial niche in mice
Gopal, A., Ibrahim, R., Fuller, M., Umlandt, P., Parker, J., Tran, J., Chang, L., Wegrzyn-Woltosz, J., Lam, J., Li, J., et al. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20200731 · Cited by 20
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 20
Yue, J., Li, J. J., Ma, J., Zhai, Y., Shen, L., Zhang, W., Li, L., & Fu, R. (2023) · Hematology · doi:10.1080/16078454.2023.2166333 · Cited by 20
Cull, A. H., Mahendru, D., Snetsinger, B., Good, D. J., Tyryshkin, K., Chesney, A. E., Ghorab, Z., Reis, M. D., Buckstein, R. J., Wells, R. A., et al. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.12.003 · Cited by 20
Alzheimer’s Disease Genetics: A Dampened Microglial Response?
Chatila, Z. K., & Bradshaw, E. M. (2021) · The Neuroscientist · doi:10.1177/10738584211024531 · Cited by 20
Greenplate, A. R., Johnson, D. B., Roussel, M., Savona, M. R., Sosman, J. A., Puzanov, I. J., Ferrell, P. B., & Irish, J. M. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0213 · Cited by 19
The Rising Era of Immune Checkpoint Inhibitors in Myelodysplastic Syndromes
Chokr, N., Patel, R. D., Wattamwar, K., & Chokr, S. (2018) · Advances in Hematology · doi:10.1155/2018/2458679 · Cited by 19
Non-canonical roles of Siglecs: Beyond sialic acid-binding and immune cell modulation
Siddiqui, S. S. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101145 · Cited by 18
Immune dysregulation and potential targeted therapy in myelodysplastic syndrome
Zhang, X., Yang, X., Ma, L., Zhang, Y., & Wei, J. (2023) · Therapeutic Advances in Hematology · doi:10.1177/20406207231183330 · Cited by 19
Inactivation of DAP12 in PMN Inhibits TREM1-Mediated Activation in Rheumatoid Arthritis
Chen, X., Eksioglu, E. A., Carter, J. D., Fortenbery, N. R., Donatelli, S. S., Zhou, J., Liu, J., Yang, L., Gilvary, D. L., Djeu, J. Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115116 · Cited by 20
Self-citationStoner, S. A., Yan, M., Liu, K. T. H., Arimoto, K., Shima, T., Wang, H., Johnson, D. T., Bejar, R. L., Jamieson, C. H. M., Guan, K., et al. (2019) · Blood · doi:10.1182/blood.2019000170 · Cited by 19
Self-citationReduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromes
Sand, K. E., Theorell, J., Bruserud, Ø., Bryceson, Y. T., & Kittang, A. O. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1865-y · Cited by 18
Agrati, C., Tumino, N., Bordoni, V., Pinnetti, C., Sabatini, A., Amendola, A., Abbate, I., Lorenzini, P., Mondi, A., Casetti, R., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01886 · Cited by 18
Diagnostic algorithm for lower-risk myelodysplastic syndromes
Mufti, G. J., McLornan, D. P., van de Loosdrecht, A. A., Germing, U., & Hasserjian, R. P. (2018) · Leukemia · doi:10.1038/s41375-018-0173-2 · Cited by 18
Kaphan, É., Laurin, D., Lafeuillade, B., Drillat, P., & Park, S. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100649 · Cited by 17
Down-regulation of EZH2 expression in myelodysplastic syndromes
Cabrero, M., Wei, Y., Yang, H., Gañán‐Gómez, I., Bohannan, Z., Colla, S., Marchesini, M., Bravo, G. M., Takahashi, K., Bueso-Ramos, C., et al. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.02.009 · Cited by 18
New Insights into the Pathogenesis of MDS and the rational therapeutic opportunities
Zahr, A. A., Bernabe, C., Wozney, J. L., Prébet, T., & Zeidan, A. M. (2016) · Expert Review of Hematology · doi:10.1586/17474086.2016.1135047 · Cited by 17
Oganesyan, A., Hakobyan, Y. K., Terrier, B., Georgin‐Lavialle, S., & MEKINIAN, A. (2021) · Seminars in Hematology · doi:10.1053/j.seminhematol.2021.10.003 · Cited by 17
Fozza, C., Murtas, A., Caocci, G., & Nasa, G. L. (2022) · Leukemia Research · doi:10.1016/j.leukres.2022.106856 · Cited by 16
HIV portends a poor prognosis in myelodysplastic syndromes
Kaner, J. D., Thibaud, S., Jasra, S., Wang, Y., Janakiram, M., Sharma, A., Sridharan, A., Elias, H. K., Polineni, R. D., Assal, A., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633631 · Cited by 15
Tsirogianni, M., Grigoriou, E., Kapsimalli, V., Dagla, K., Stamouli, M., Gkirkas, K., Konsta, E., Karagiannidou, A., Gkodopoulos, K., Stavroulaki, G., et al. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1581935 · Cited by 16
Emerging biological therapies for the treatment of myelodysplastic syndromes
Zeidan, A. M., Stahl, M. F., & Komrokji, R. S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1220534 · Cited by 15
Shallis, R. M., Chokr, N., Stahl, M. F., Pine, A. B., & Zeidan, A. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1503049 · Cited by 15
Zeidan, A. M., Cook, R. J., Bordoni, R. E., Berenson, J. R., Edenfield, W. J., Mohan, S. R., Zhou, G., Asatiani, E., Srinivas, N., & Savona, M. R. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.01.012 · Cited by 16
The Role of BCL-2 and PD-1/PD-L1 Pathway in Pathogenesis of Myelodysplastic Syndromes
Kuszczak, B., Wróbel, T., Wicherska‐Pawłowska, K., & Rybka, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054708 · Cited by 15
Jen, W., Konopleva, M. Y., & Pemmaraju, N. (2024) · Cancer · doi:10.1002/cncr.35315 · Cited by 15
S100A9: The Unusual Suspect Connecting Viral Infection and Inflammation
Boucher, J., Gilbert, C., Bose, S., & Tessier, P. A. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300640 · Cited by 15
Bravo, G. M., Thongon, N., Rodríguez‐Sevilla, J. J., Ma, F., Gañán‐Gómez, I., Yang, H., Kim, Y. J., Ademà, V., Wildeman, B., Tanaka, T. N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101585 · Cited by 14
Inflammasome Activation in Myeloid Malignancies—Friend or Foe?
Andina, N. D., Bonadies, N., & Allam, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.825611 · Cited by 15
Wang, Y., Lin, C., Yao, C., Amaral, F. M. R., Yu, S., Kao, C., Shih, P., Hou, H., Chou, W., & Tien, H. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022008958 · Cited by 14
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
Tentori, C. A., Zhao, L., Tinterri, B., Strange, K. E., Zoldan, K., Dimopoulos, K., Feng, X., Riva, E., Lim, B., Simoni, Y., et al. (2024) · HemaSphere · doi:10.1002/hem3.64 · Cited by 14
Immunobiology of S100A8 and S100A9 Proteins and Their Role in Acute Inflammation and Sepsis
Gazzar, M. E. (2015) · International Journal of Immunology and Immunotherapy · doi:10.23937/2378-3672/1410013 · Cited by 14
Role of macrophages and phagocytes in orchestrating normal and pathologic hematopoietic niches
Lévesque, J.-P., SUMMERS, K. M., Millard, S. M., Bisht, K., Winkler, I. G., & Pettit, A. R. (2021) · Experimental Hematology · doi:10.1016/j.exphem.2021.07.001 · Cited by 17
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
Carraway, H. E. (2016) · Hematology · doi:10.1182/asheducation-2016.1.470 · Cited by 13
Inflammatory and Immune Disorders Associated with Myelodysplastic Syndromes
Jachiet, V., Fenaux, P., Sevoyan, A., Hakobyan, Y. K., Adès, L., Fain, O., MEKINIAN, A., & GFM, O. B. O. T. M. A. (2021) · Hemato · doi:10.3390/hemato2020019 · Cited by 16
Cull, A. H., & Rauh, M. J. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.5ri0317-083r · Cited by 13
Mass cytometry defines distinct immune profile in germinal center B-cell lymphomas
Roussel, M., Lhomme, F., Roe, C. E., Bartkowiak, T., Gravelle, P., Laurent, C., Fest, T., & Irish, J. M. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02464-z · Cited by 14
Srivastava, P., Tzetzo, S. L., Gomez, E. C., Eng, K. H., Sait, S. N. J., Kuechle, J., Singh, P. K., de Jong, K., Wiatrowski, K., Peresie, J., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0765-5 · Cited by 13
New Perspectives on Myeloid-Derived Suppressor Cells and Their Emerging Role in Haematology
Bizymi, N., Matthaiou, A. Μ., Matheakakis, A., Voulgari, I., Aresti, N., Zavitsanou, K., Karasachinidis, A., Mavroudi, I., Pontikoglou, C. G., & Papadaki, H. Α. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185326 · Cited by 12
Bahmani, F., Shayanmanesh, M., Safari, M., Alaei, A., Pouriafar, Y., Rasti, Z., Zaker, F., Rostami, S., Damerchiloo, F., & Safa, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03793-z · Cited by 12
Oßwald, L., Hamarsheh, S., Uhl, F. M., Andrieux, G., Klein, C., Dierks, C., Duquesne, S., Braun, L. M., Schmitt-Graeff, A. H., Duyster, J., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-20-0275 · Cited by 12
Keltsch, E., Greiner, J., Wahl, L., Knape, I., Tews, D., Denkinger, M. D., Debatin, K., & Strauß, G. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00524-w · Cited by 11
SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
Sallman, D. A., Tanaka, T. N., List, A. F., & Bejar, R. L. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.09.018 · Cited by 12
Self-citation
Metadata
- Authors
- Chen, X., Eksioglu, E. A., Zhou, J., Zhang, L., Djeu, J., Fortenbery, N., Epling-Burnette, P., Van Bijnen, S., Dolstra, H., Cannon, J., Youn, J.-I., Donatelli, S. S., Qin, D., De Witte, T., Tao, J., Wang, H., Cheng, P., Gabrilovich, D. I., List, A., & Wei, S.
- Affiliations
- Moffitt Cancer Center (US)
- Radboud University Medical Center (NL)
- University of South Florida (US)
- Corresponding author
- Wei, Sheng
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2013-10-15
- Volume
- 123
- Issue
- 11
- Pages
- 4595-4611
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3809779
- OpenAlex
- W2111063688
- Cited by
- 316
- References
- 63
- Citations by year
- 2026: 17 · 2025: 18 · 2024: 19 · 2023: 28 · 2022: 31 · 2021: 43 · 2020: 30 · 2019: 26 · 2018: 23 · 2017: 25 · 2016: 30 · 2015: 17 · 2014: 9
- FWCI
- 10.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- National Institutes of Health (AI056213)
- National Cancer Institute (T32CA115308, R01CA131076, R01CA100062, P30CA076292)
- National Institute of Allergy and Infectious Diseases (AI056213, R01AI056213)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- myelodysplastic syndrome, myeloid-derived suppressor cells, ineffective hematopoiesis, S100A9, CD33, immunoreceptor tyrosine-based inhibition motif, ITAM, DAP12, IL-10, TGF-beta, bone marrow, all-trans retinoic acid, transgenic mice
- MeSH terms
- Animals, Disease Models, Animal, Female, Hematopoiesis, HLA-DR Antigens, Humans, Ligands, Male, Mice, Transgenic, Myelodysplastic Syndromes, Signal Transduction, Mice, Knockout, Adoptive Transfer, Myeloid Cells, Calgranulin A, Calgranulin B, Mice, Cellular Microenvironment, Sialic Acid Binding Ig-like Lectin 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
